GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune
ASH is just over a month away. Come meet with the GTC team and its co-op partners at our happy hour event. Download your invitation
Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of
A Man with a Recurrent Left Pleural Effusion In late 2020, a new disease entity that was referred to as VEXAS (vacuoles, E1 enzyme, X-linked,
GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in
Jul 23, 2020 | John Gilmore NEW YORK – As part of plans to establish a country-wide network of labs for minimizing the cost of
GTC is the first and only diagnostic lab to deploy true artificial intelligence (AI) software for classifications of lymphoma. Do not accept partial results, send
IRVINE, Calif. and EDISON, N.J., July 22, 2020 /PRNewswire/ — Hackensack Meridian Health (HMH) in Edison, New Jersey, and Genomic Testing Cooperative (GTC), Irvine, California, announced
